The iBio VLP platform is based on the production of non-enveloped virus-like particles composed of viral core proteins that self-assemble into spherical particles. This type of VLP, with one major protein component, is:
iBio VLP platform (non-enveloped VLP)
VLP-based vaccines interact with immune cells differently than soluble antigens. The size and repetitive antigen presentation of VLPs have been demonstrated to trigger both humoral and cellular responses, but more importantly to generate memory cells and long-lasting plasma cells, potentially providing years of protection without compromising safety.1,2
iBio is currently developing IBIO-200, a VLP-based vaccine candidate in which a SARS-CoV-2 antigen is fused to a self-assembling protein partner and displayed in a repetitive structure and geometry, decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.